Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Huisarts en wetenschap 3/2011

01-03-2011 | Onderzoek

Een elektrocardiogram bij elke patiënt met hypertensie

Auteurs: Margriet de Beus, Arno Hoes, Frans Rutten, Mattijs Numans, Rick Grobbee, Tjarda Scheltens, Arend Mosterd, Jan Kors, Michiel Bots

Gepubliceerd in: Huisarts en wetenschap | Uitgave 3/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Scheltens T, De Beus MF, Hoes AW, Rutten FH, Numans ME, Mosterd A, et al. Een elektrocardiogram bij elke patiënt met hypertensie. Huisarts Wet 2011;54(3):122-7.
Doel Een aantal bestaande richtlijnen adviseert om bij hypertensiepatiënten een elektrocardiogram te maken om het cardiovasculaire risico nauwkeuriger te kunnen schatten. We onderzochten de prevalentie van klinisch relevante ecg-afwijkingen in deze patiëntengroep en maakten een schatting van het number needed to screen (NNS): het aantal ecg’s dat men bij hypertensiepatiënten moet maken om bij adequate behandeling gedurende tien jaar één sterfgeval te voorkomen.
Methode De onderzoekspopulatie bestond uit 866 hypertensiepatiënten van het Leidsche Rijn Gezondheidsproject (een cohortonderzoek in Leidsche Rijn bij Utrecht). Met behulp van de SCORE-tabel (Systematic COronary Risk Evaluation) hebben we bij hen alle risicofactoren gemeten die nodig zijn voor een risicoschatting, waarna we een ecg maakten. We interpreteerden dit met behulp van het Modular ECG Analysis System (MEANS). We berekenden het NNS om één sterfgeval te voorkomen met behulp van de inverse prevalentie (1/prevalentie) van ecg-afwijkingen, vermenigvuldigd met het number needed to treat (NNT): het aantal patiënten dat men moet behandelen om één sterfgeval te voorkomen door behandeling van de ecg-afwijkingen conform bestaande richtlijnen.
Resultaten De populatie bestond voor 54,2% uit mannen en was gemiddeld 53,2 jaar oud (sd 11,5). De prevalentie van ecg-afwijkingen was 17,6% (95%-BI 15,0-20,1). Atriumfibrilleren en myocardinfarct kwamen voor bij 2,1% (95%-BI 1,1-3,0). De prevalentie van andere ecg-afwijkingen die de kans op hart- en vaatziekten (HVZ) verhogen was 15,4% (95%-BI 13,1-17,9). Het NNS om één sterfgeval door HVZ in tien jaar te voorkomen schatten we op 260 (95%-BI 220-308).
Conclusie Deze bevindingen ondersteunen richtlijnen die aanbevelen om een ecg te maken bij hypertensiepatiënten. De prevalentie van klinisch relevante afwijkingen is namelijk aanzienlijk en het NNS om één sterfgeval te voorkomen is lager dan bij andere algemeen geaccepteerde tests.
UMC Utrecht, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Postbus 85060, 3508 AB Utrecht: dr. T. Scheltens, huisarts; dr. M.F. de Beus, arts onderzoeker; prof.dr. A.W. Hoes, hoogleraar klinische epidemiologie en huisartsgeneeskunde; dr. F.H. Rutten, huisarts en onderzoeker; prof.dr. M.E. Numans, hoogleraar huisartsgeneeskunde; dr. A. Mosterd, cardioloog; prof.dr. D.E. Grobbee, hoogleraar klinische epidemiologie; prof.dr. M.L. Bots, hoogleraar epidemiologie. UMC Utrecht, afdeling Cardiologie: dr. M.F. de Beus, cardioloog in opleiding; dr. A. Mosterd, cardioloog. Erasmus Universiteit Rotterdam, afdeling Medische Informatica: dr. J.A. Kors, universitair hoofddocent medische informatica. Meander Medisch Centrum, afdeling Cardiologie: dr. A. Mosterd, cardioloog. VUmc Amsterdam, afdeling Huisartsgeneeskunde: prof. dr. M.E. Numans, hoogleraar huisartsgeneeskunde.
Correspondentie: t.scheltens@umcutrecht.nl
Mogelijke belangenverstrengeling: niets aangegeven.
Dit artikel is een bewerkte vertaling van: Scheltens T, De Beus MF, Hoes AW, Rutten FH, Numans ME, Mosterd A, et al. The potential yield of ECG screening of hypertensive subjects: The Utrecht Health Project. J Hypertens 2010;28:1527-33. Publicatie gebeurt met toestemming van de uitgever.
Literatuur
1.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003. PubMedCrossRef Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003. PubMedCrossRef
2.
go back to reference Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:S1–113. PubMedCrossRef Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:S1–113. PubMedCrossRef
3.
go back to reference Mancia G, De Backer BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462–536. PubMed Mancia G, De Backer BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462–536. PubMed
4.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52. PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52. PubMedCrossRef
5.
go back to reference Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634–40. PubMedCrossRef Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634–40. PubMedCrossRef
6.
go back to reference Kelm M. Minor electrocardiogram abnormalities in arterial hypertension: does it matter? J Hypertens 2004;22:261–3. PubMedCrossRef Kelm M. Minor electrocardiogram abnormalities in arterial hypertension: does it matter? J Hypertens 2004;22:261–3. PubMedCrossRef
7.
go back to reference Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005;23:S27–S33. PubMedCrossRef Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005;23:S27–S33. PubMedCrossRef
8.
go back to reference JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 Suppl 5:v1–52. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 Suppl 5:v1–52.
9.
go back to reference Smulders YM, Burgers JS, Scheltens T, Van Hout BA, Wiersma T, Simoons ML. Clinical practice guideline for cardiovascular risk management in the Netherlands. Neth J Med 2008;66:169–74. PubMed Smulders YM, Burgers JS, Scheltens T, Van Hout BA, Wiersma T, Simoons ML. Clinical practice guideline for cardiovascular risk management in the Netherlands. Neth J Med 2008;66:169–74. PubMed
10.
go back to reference Ashley EA, Raxwal VK, Froelicher VF. The prevalence and prognostic significance of electrocardiographic abnormalities. Curr Probl Cardiol 2000;25:1–72. PubMedCrossRef Ashley EA, Raxwal VK, Froelicher VF. The prevalence and prognostic significance of electrocardiographic abnormalities. Curr Probl Cardiol 2000;25:1–72. PubMedCrossRef
11.
go back to reference De Bacquer BD, De Backer BG, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 1998;80:570–7. PubMed De Bacquer BD, De Backer BG, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 1998;80:570–7. PubMed
12.
go back to reference Kumar A, Lloyd-Jones DM. Clinical significance of minor nonspecific ST-segment and T-wave abnormalities in asymptomatic subjects: a systematic review. Cardiol Rev 2007;15:133–42. PubMedCrossRef Kumar A, Lloyd-Jones DM. Clinical significance of minor nonspecific ST-segment and T-wave abnormalities in asymptomatic subjects: a systematic review. Cardiol Rev 2007;15:133–42. PubMedCrossRef
13.
go back to reference Grobbee DE, Hoes AW, Verheij TJ, Schrijvers AJ, Van Ameijden EJ, Numans ME. The Utrecht Health Project: optimization of routine healthcare data for research. Eur J Epidemiol 2005;20:285–7. PubMedCrossRef Grobbee DE, Hoes AW, Verheij TJ, Schrijvers AJ, Van Ameijden EJ, Numans ME. The Utrecht Health Project: optimization of routine healthcare data for research. Eur J Epidemiol 2005;20:285–7. PubMedCrossRef
14.
go back to reference Van Bemmel JH, Kors JA, Van Herpen G. Methodology of the modular ECG analysis system MEANS. Methods Inf Med 1990;29:346–53. PubMed Van Bemmel JH, Kors JA, Van Herpen G. Methodology of the modular ECG analysis system MEANS. Methods Inf Med 1990;29:346–53. PubMed
15.
go back to reference De Bruyne MC, Kors JA, Hoes AW, Kruijssen DA, Deckers JW, Grosfeld M, et al. Diagnostic interpretation of electrocardiograms in population- based research: computer program research physicians, or cardiologists? J Clin Epidemiol 1997;50:947–52. PubMedCrossRef De Bruyne MC, Kors JA, Hoes AW, Kruijssen DA, Deckers JW, Grosfeld M, et al. Diagnostic interpretation of electrocardiograms in population- based research: computer program research physicians, or cardiologists? J Clin Epidemiol 1997;50:947–52. PubMedCrossRef
16.
go back to reference De Bruyne MC, Kors JA, Visentin S, Van Herpen G, Hoes AW, Grobbee DE, et al. Reproducibility of computerized ECG measurements and coding in a nonhospitalized elderly population. J Electrocardiol 1998;31:189–95. PubMedCrossRef De Bruyne MC, Kors JA, Visentin S, Van Herpen G, Hoes AW, Grobbee DE, et al. Reproducibility of computerized ECG measurements and coding in a nonhospitalized elderly population. J Electrocardiol 1998;31:189–95. PubMedCrossRef
17.
go back to reference Pelliccia A, Maron BJ, Culasso F, Di Paolo FM, Spataro A, Biffi A, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000;102:278–84. PubMed Pelliccia A, Maron BJ, Culasso F, Di Paolo FM, Spataro A, Biffi A, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000;102:278–84. PubMed
18.
go back to reference Boomsma LJ, Van Lidth de Jeude CP. ‘Number needed to screen’: een hulpmiddel bij de beoordeling van preventieprogramma’s. Ned Tijdschr Geneeskd 2000;144:2345–8. PubMed Boomsma LJ, Van Lidth de Jeude CP. ‘Number needed to screen’: een hulpmiddel bij de beoordeling van preventieprogramma’s. Ned Tijdschr Geneeskd 2000;144:2345–8. PubMed
19.
go back to reference Ammar KA, Kors JA, Yawn BP, Rodeheffer RJ. Defining unrecognized myocardial infarction: a call for standardized electrocardiographic diagnostic criteria. Am Heart J 2004;148:277–84. PubMedCrossRef Ammar KA, Kors JA, Yawn BP, Rodeheffer RJ. Defining unrecognized myocardial infarction: a call for standardized electrocardiographic diagnostic criteria. Am Heart J 2004;148:277–84. PubMedCrossRef
20.
go back to reference Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000;140:848–56. PubMedCrossRef Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000;140:848–56. PubMedCrossRef
21.
go back to reference Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345–52. PubMed Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345–52. PubMed
22.
go back to reference Vagaonescu TD, Wilson AC, Kostis JB. Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. Hypertension 2008;51:1552–6. PubMedCrossRef Vagaonescu TD, Wilson AC, Kostis JB. Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. Hypertension 2008;51:1552–6. PubMedCrossRef
23.
go back to reference Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449–57. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449–57.
24.
go back to reference Sever PS, Poulter NR, Dahlof B, Wedel H. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009;27:947–54. PubMedCrossRef Sever PS, Poulter NR, Dahlof B, Wedel H. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009;27:947–54. PubMedCrossRef
25.
go back to reference Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. PubMedCrossRef Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. PubMedCrossRef
26.
go back to reference Lozano JV, Redon J, Cea-Calvo L, Fernandez-Perez C, Navarro J, Bonet A, et al. [Left ventricular hypertrophy in the Spanish hypertensive population. The ERIC-HTA study]. Rev Esp Cardiol 2006;59:136–42. PubMedCrossRef Lozano JV, Redon J, Cea-Calvo L, Fernandez-Perez C, Navarro J, Bonet A, et al. [Left ventricular hypertrophy in the Spanish hypertensive population. The ERIC-HTA study]. Rev Esp Cardiol 2006;59:136–42. PubMedCrossRef
27.
go back to reference Bestehorn K, Wahle K, Kirch W. Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. Clin Drug Investig 2008;28:281–9. PubMedCrossRef Bestehorn K, Wahle K, Kirch W. Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. Clin Drug Investig 2008;28:281–9. PubMedCrossRef
28.
go back to reference Peer N, Steyn K, Dennison CR, Levitt NS, Nyo MT, Nel JH, et al. Determinants of target organ damage in black hypertensive patients attending primary health care services in Cape Town: the Hi-Hi study. Am J Hypertens 2008;21:896–902. PubMedCrossRef Peer N, Steyn K, Dennison CR, Levitt NS, Nyo MT, Nel JH, et al. Determinants of target organ damage in black hypertensive patients attending primary health care services in Cape Town: the Hi-Hi study. Am J Hypertens 2008;21:896–902. PubMedCrossRef
29.
go back to reference Martinez MA, Sancho T, Armada E, Rubio JM, Anton JL, Torre A, et al. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. Am J Hypertens 2003;16:556–63. PubMedCrossRef Martinez MA, Sancho T, Armada E, Rubio JM, Anton JL, Torre A, et al. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. Am J Hypertens 2003;16:556–63. PubMedCrossRef
30.
go back to reference Cohen JD. Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT. Am J Cardiol 1992;70:14F–18F. PubMedCrossRef Cohen JD. Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT. Am J Cardiol 1992;70:14F–18F. PubMedCrossRef
31.
go back to reference Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens 2003;16:646–52. PubMedCrossRef Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens 2003;16:646–52. PubMedCrossRef
32.
go back to reference Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31. PubMedCrossRef Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31. PubMedCrossRef
33.
go back to reference Sierra C, De la Sierra SA. Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag 2008;4:289–96. PubMed Sierra C, De la Sierra SA. Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag 2008;4:289–96. PubMed
34.
go back to reference Schillaci G, Pirro M, Pasqualini L, Vaudo G, Ronti T, Gemelli F, et al. Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. J Hypertens 2004;22:407–14. PubMedCrossRef Schillaci G, Pirro M, Pasqualini L, Vaudo G, Ronti T, Gemelli F, et al. Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. J Hypertens 2004;22:407–14. PubMedCrossRef
35.
go back to reference Macfarlane PW, Norrie J. The value of the electrocardiogram in risk assessment in primary prevention: Experience from the West of Scotland Coronary Prevention Study. J Electrocardiol 2007;40:101–9. PubMedCrossRef Macfarlane PW, Norrie J. The value of the electrocardiogram in risk assessment in primary prevention: Experience from the West of Scotland Coronary Prevention Study. J Electrocardiol 2007;40:101–9. PubMedCrossRef
36.
go back to reference Klungel OH, De Boer A, Paes AH, Nagelkerke NJ, Seidell JC, Bakker A. Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. J Clin Epidemiol 2000;53:1158–63. PubMedCrossRef Klungel OH, De Boer A, Paes AH, Nagelkerke NJ, Seidell JC, Bakker A. Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. J Clin Epidemiol 2000;53:1158–63. PubMedCrossRef
37.
go back to reference Stafford RS, Misra B. Variation in routine electrocardiogram use in academic primary care practice. Arch Intern Med 2001;161:2351–5. PubMedCrossRef Stafford RS, Misra B. Variation in routine electrocardiogram use in academic primary care practice. Arch Intern Med 2001;161:2351–5. PubMedCrossRef
38.
go back to reference Wassenberg MW, Willemsen JM, Gaillard CA, Braam B. Hypertension management in primary care: standard care and attitude towards a disease management model. Neth J Med 2004;62:375–82. PubMed Wassenberg MW, Willemsen JM, Gaillard CA, Braam B. Hypertension management in primary care: standard care and attitude towards a disease management model. Neth J Med 2004;62:375–82. PubMed
39.
go back to reference Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998;317:307–12. PubMedCrossRef Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998;317:307–12. PubMedCrossRef
40.
go back to reference Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician 2001;63:513–22. PubMed Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician 2001;63:513–22. PubMed
Metagegevens
Titel
Een elektrocardiogram bij elke patiënt met hypertensie
Auteurs
Margriet de Beus
Arno Hoes
Frans Rutten
Mattijs Numans
Rick Grobbee
Tjarda Scheltens
Arend Mosterd
Jan Kors
Michiel Bots
Publicatiedatum
01-03-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 3/2011
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/s12445-011-0063-6